BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026. The call can be accessed via teleconference at: Q3 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

Group 1 - Haemonetics Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 7:30 am Pacific Time [1] - The presentation will be accessible via a live audio webcast and will be available for replay for 30 days after the event [1] - Haemonetics is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency [2] Group 2 - The company offers innovative solutions including hospital technologies, plasma collection technologies, and products for blood centers [2] - Haemonetics aims to advance standards of care and enhance patient outcomes through its technologies [2]

Core Insights - Loomis Sayles Small Cap Value Fund reported a return of 6.21% in Q3 2025, underperforming the Russell 2000 Value Index which returned 12.60% [1] - The strong performance of US equities in Q3 was attributed to easing tariff concerns, a pro-growth budget from Congress, and expectations of further rate cuts by the Federal Reserve [1] Company Performance - Haemonetics Corporation (NYSE:HAE) had a one-month return of -0.92% and a 52-week gain of 3.36%, with its stock closing at $80.01 and a market capitalization of $3.855 billion on December 24, 2025 [2] - The company reported a revenue of $327 million in Q2 of fiscal 2026, reflecting a 5% decline compared to previous periods [4] Investment Strategy - The fund's performance was impacted by a market shift towards "risk-on" and "low-quality" stocks, which led to a style mismatch with the fund's high-quality investment approach [3] - Haemonetics Corporation, along with Alight, Inc. and Kyndryl Holdings Incorporated, was noted as a significant detractor from the fund's performance [3]

Core Insights - Riverwater Partners' Small Cap Strategy reported solid results for Q3 2025 but lagged behind the benchmark due to the market's preference for lower-quality companies [1] - The strategy focuses on higher-quality companies with strong fundamentals and a clear path to profitability, positioning itself well in a challenging market [1] Company Performance - Haemonetics Corporation (NYSE:HAE) had a one-month return of 8.06% but experienced a 2.03% decline over the last 52 weeks, closing at $80.40 per share with a market capitalization of $3.873 billion [2] - The company faced challenges due to softer-than-expected demand in certain product lines, leading to a decision to exit the position in Q3 2025 to redeploy capital into opportunities with clearer near-term catalysts [3] Revenue and Market Position - In Q2 of fiscal 2026, Haemonetics reported revenue of $327 million, reflecting a 5% decline [4] - Despite its potential, Haemonetics is not among the most popular stocks among hedge funds, with 36 hedge fund portfolios holding its shares at the end of Q3, up from 29 in the previous quarter [4]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Key Takeaways Haemonetics sees growth led by Hospital recovery and strong NexSys PCS momentum. HAE's NexSys PCS gains from Persona rollout, higher yields and faster donor processing times. HAE's Hospital revenue rose 5% with solid Blood Management Technologies and Vascular Closure gains. Haemonetics Corporation’s (HAE) impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. However, a dull macr ...

–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P– RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of an oral pellet formulation ...

Core Insights - Pharvaris (PHVS) shares increased nearly 22% following positive results from the phase III RAPIDe-3 study for its drug deucrictibant, aimed at treating hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older [2][8] Study Results - The RAPIDe-3 study achieved its primary endpoint, with patients experiencing symptom relief within 1.28 hours after taking deucrictibant, compared to over 12 hours with placebo [3] - All secondary endpoints were met, including a median time to substantial symptom relief of under 3 hours with deucrictibant versus over 12 hours with placebo, and complete symptom resolution in 11.95 hours compared to more than 24 hours for placebo [3] - 83% of HAE attacks were managed with a single dose of deucrictibant, and over 93% of attacks were treated without the need for backup treatment [4] Regulatory Plans - Pharvaris plans to submit a regulatory filing for deucrictibant in the first half of 2026, which could position it as the second oral on-demand therapy for HAE after KalVista Pharmaceuticals' Ekterly [5] Competitive Landscape - Comparisons between deucrictibant and KalVista's Ekterly highlight potential advantages for deucrictibant, as it showed faster symptom relief in the RAPIDe-3 study compared to the KONFIDENT study supporting Ekterly's approval [6] - Year-to-date, Pharvaris stock has risen 53%, outperforming the industry growth of 20% [7] Product Development - Pharvaris is developing two formulations of deucrictibant: an immediate-release capsule for acute treatment and an extended-release tablet for prophylactic treatment [10] - The extended-release tablet is being evaluated in the phase III CHAPTER-3 study for HAE prophylaxis, with top-line data expected in the second half of 2026 [11] - Additionally, the extended-release formulation is under evaluation in the CREAATE study for treating acquired angioedema with C1-inhibitor deficiency [12] Market Positioning - If approved, deucrictibant will compete in the on-demand treatment space against KalVista's Ekterly, with advantages over older injectable treatments like Firazyr and Kalbitor due to its oral administration [14] - In the prophylactic treatment segment, competitors include BioCryst Pharmaceuticals and Ionis Pharmaceuticals, with BioCryst's Orladeyo and Ionis' Dawnzera being notable products [15]

Group 1: Market Overview - As of December 2, 2025, two stocks in the health care sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] Group 2: Company Analysis - Exact Sciences Corp - Abbott Laboratories agreed to acquire Exact Sciences for $105 per common share, totaling approximately $21 billion in equity value and an estimated enterprise value of $23 billion, marking the largest deal in the global health-care sector for the year [7] - Exact Sciences' stock has increased by around 51% over the past month, with a 52-week high of $101.87 [7] - The RSI value for Exact Sciences is reported at 89.8, indicating it is overbought [7] - On the latest trading day, shares of Exact Sciences fell by 0.1% to close at $101.20 [7] Group 3: Company Analysis - Haemonetics Corp - Haemonetics reported strong second-quarter earnings, with earnings per share of $1.27, surpassing the analyst consensus estimate of $1.11 [7] - The company also reported quarterly sales of $327.316 million, exceeding the analyst consensus estimate of $311.399 million [7] - Haemonetics' stock has gained approximately 61% over the past month, with a 52-week high of $88.31 [7] - The RSI value for Haemonetics is reported at 89.4, indicating it is also overbought [7] - On the latest trading day, shares of Haemonetics fell by 0.5% to close at $80.96 [7]

Group 1: Market Overview - As of December 2, 2025, two stocks in the health care sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] Group 2: Company Highlights - Exact Sciences Corp (NASDAQ:EXAS) is involved in a significant acquisition by Abbott Laboratories for $105 per share, totaling approximately $21 billion in equity value [7] - Exact Sciences' stock has increased by around 51% over the past month, with a 52-week high of $101.87 and an RSI value of 89.8 [7] - Haemonetics Corp (NYSE:HAE) reported strong second-quarter earnings, with earnings per share of $1.27, surpassing the consensus estimate of $1.11 [7] - Haemonetics' quarterly sales reached $327.316 million, exceeding the analyst consensus estimate of $311.399 million, and the stock has gained approximately 61% over the past month [7] - Haemonetics has a 52-week high of $88.31 and an RSI value of 89.4 [7]